For example, early interventions targeting oxidative stress and inflammation (e.g., antioxidants and anti-inflammatory agents) may be more critical in the ≤5 y group, while strategies to enhance stress response pathways (e.g., SUMO1-related therapies) could be explored in chronic PTSD. The gene discussed is SUMO1; the disease is post-traumatic stress disorder.